On October 7, 2025, Carolina Wealth Advisors, LLC reported purchasing shares of Novo Nordisk A/S (NYSE: NVO) worth approximately $6.01 million, calculated using the average price from the third quarter of 2025.
What happened
Carolina Wealth Advisors, LLC recently increased its investment in Novo Nordisk. A filing with the Securities and Exchange Commission (SEC) shows they added 102,629 shares during the July-September quarter of 2025. This purchase was worth approximately $6.01 million, based on average share prices during that period. As of October 7, 2025, Carolina Wealth Advisors now holds a total of 116,973 shares of Novo Nordisk.
What else to know
This purchase increased Novo Nordisk A/S to 2.8% of the fund’s total assets reported on its 13F filing as of the third quarter of 2025.
Top holdings after the filing:
- NYSEMKT:SCHQ: $18.93 million (8.2% of AUM) as of September 30, 2025.
- NYSEMKT:BKAG: $13.22 million (5.7% of AUM) as of September 30, 2025.
- NYSEMKT:SCHP: $13.10 million (5.6589% of AUM) as of September 30, 2025.
- NYSE:DELL: $10.14 million (4.3781% of AUM) as of September 30, 2025.
- NYSEMKT:SPHY: $10.09 million (4.3568% of AUM) as of Q3 2025.
On October 6, 2025, Novo Nordisk A/S stock closed at $59.65. Over the last year, the stock has performed 65.4% worse than the S&P 500.
Company Overview
| Metric | Value |
|---|---|
| Price (as of market close 2025-10-06) | $59.65 |
| Market Capitalization | $260.30 billion |
| Revenue (TTM) | $49.25 billion |
| Net Income (TTM) | $17.54 billion |
Company Snapshot
Novo Nordisk:
- Offers pharmaceutical products focused on diabetes, obesity, cardiovascular, rare blood disorders, and hormone replacement therapies, as well as medical devices such as insulin pens and smart diabetes solutions.
- Generates revenue primarily through the development, manufacturing, and global distribution of branded prescription medicines and medical devices, with a strong focus on chronic disease management.
- Serves healthcare providers, hospitals, and patients in Europe, North America, Asia, and other international markets, targeting individuals with diabetes, obesity, and rare diseases.
Novo Nordisk is a leading global healthcare company focused on treating diabetes and obesity, and also developing therapies for rare diseases. They create innovative medicines and medical devices through significant investment in research. With a wide range of products and a worldwide presence, Novo Nordisk is a major player in managing long-term health conditions.
Foolish take
Carolina Wealth Advisors recently increased its investment in Novo Nordisk by $6 million, significantly expanding their stake from half a percent to 2.8% of their total portfolio.
This investment makes Novo Nordisk, the company behind Ozempic and Wegovy, the eleventh-biggest position in our overall investment portfolio, and our sixth-largest stock holding.
Considering Carolina Wealth dedicates nearly a third of its investments to bond and treasury ETFs, its growing investment in Novo Nordisk is particularly noteworthy.
Novo Nordisk’s stock price has fallen almost 60% from its peak over the past two years, making now a potentially good time for an acquisition.
In 2024, the company’s stock price reached record levels thanks to successful new drugs for obesity and diabetes, causing its price-to-earnings ratio to jump to 50.
These exciting new developments are attracting more competition. As a result, Novo Nordisk’s stock price has become more moderate, currently trading at 19 times earnings, while the company assesses how much of its dominant market position it can maintain.
If investors continue to have confidence in Novo Nordisk’s position as a market leader and its development of new drugs, the company’s current stock price could prove to be a great deal, and Carolina Wealth is taking advantage of this potential by investing.
Glossary
Here’s a breakdown of the terms used:
13F AUM: The total value of U.S. stocks held by institutional investors, as reported to the SEC every quarter.
Reportable AUM: The portion of a fund’s assets that must be publicly disclosed in regulatory filings.
Quarter (Q3 2025): The period from July 1st to September 30th of the year 2025.
Stake: The amount of ownership an investor has in a company, usually measured by the number of shares.
Top holdings: A fund’s largest investments, typically ranked by value.
Filing: An official document submitted to a regulator, like the SEC, to share financial or investment information.
Underperformance: When an investment doesn’t perform as well as a benchmark or similar investment.
Chronic disease management: Long-term medical care for conditions like diabetes or obesity.
Pharmaceutical products: Medicines used to diagnose, treat, or prevent diseases.
Medical devices: Tools and instruments used for medical diagnosis, treatment, or management.
Smart diabetes solutions: Technology, such as connected insulin pens, designed to improve diabetes management.
TTM: The most recent 12-month period.
Read More
- Gold Rate Forecast
- USD PLN PREDICTION
- MNT PREDICTION. MNT cryptocurrency
- XRP: The Smartest Crypto for $1,000?
- Why AeroVironment Stock Is Skyrocketing This Week
- MercadoLibre’s Plunge: Amazon’s Brazil Gambit
- Dividend Mirage and the Peril of Perpetual Yield
- The $1 Trillion Temptation: A Desperate Investor’s Guide to AI’s Abyss
- Bitcoin’s Chaotic Waltz: $1.3B Flows & the Illusion of Trust 🎭
- Why XRP’s Time Below $3 Might Just Be the Calm Before the Storm!
2025-10-08 22:29